Innovent Biologics

Eli Lilly transfers commercialization rights for breast cancer drug in China amid generic competition

Eli Lilly transferred mainland China commercialization rights for its breast cancer drug Verzenios to Innovent Biologics due to generic competition. Lilly will continue manufacturing and supplying the